scholarly journals Retroperitoneal hematoma following radical orchiectomy: Two cases

2017 ◽  
Vol 11 (1-2) ◽  
pp. 35 ◽  
Author(s):  
Rachel Glicksman ◽  
Robert J. Hamilton ◽  
Peter Chung
Keyword(s):  
Testicular Cancer ◽  
Metastatic Disease ◽  
Clinical Presentation ◽  
Hemodynamic Instability ◽  
Retroperitoneal Hematoma ◽  
Testicular Seminoma ◽  
Postoperative Changes ◽  
Radical Orchiectomy ◽  
Stage 1 ◽  
Progressive Anemia

Treatment of testicular cancer is dependent on the stage of disease at presentation. Stage 1 testicular cancer is treated with radical orchiectomy, followed by active surveillance, radiotherapy, or chemotherapy. Occasionally, unusual and unexpected postoperative changes can be seen on computed tomography (CT), and may raise concern for metastatic disease.Here, we present two cases of testicular cancer patients who developed retroperitoneal hematomas post-radical orchiectomy, one as a classical clinical presentation, and the other as an atypicalradiological entity only. The first is a case of a 38-year-old male with a non-seminoma testicular cancer, who developed severe flank pain, hemodynamic instability, and progressive anemia from a retroperitoneal hematoma in the immediate (<24 hours) postoperative period, requiring urgent surgical evacuation. The second is a case of a 33-year-old male with a testicular seminoma who had a large, suspicious retroperitoneal mass on a staging CT scan concerning for metastatic disease, which was later diagnosed asa retroperitoneal hematoma. These cases reveal the clinical variability with which a retroperitoneal hematoma post-radical orchiectomy may present. In addition, the second case demonstrates the importance of recognizing radiological postoperative changes and ensuring that these findings are not mistaken for and treated as metastatic disease.

Testis

2013 ◽  
Author(s):  
Peter Hoskin
Keyword(s):  
Lymph Nodes ◽  
Testicular Cancer ◽  
Metastatic Disease ◽  
Combination Chemotherapy ◽  
Palliative Treatment ◽  
Stage I ◽  
Testicular Seminoma ◽  
Resistant Disease

Chapter 8c discusses the role of radiotherapy in testicular cancer and how it is becoming less prominent. The mainstay of treatment is radical orchidectomy and, where there is a risk of metastatic disease, combination chemotherapy. Radiotherapy may be indicated in the following situations: 1) Stage I testicular seminoma delivering prophylactic para-aortic lymph nodes irradiation, and 2) Palliative treatment in the management of chemotherapy resistant disease.

Unenhanced MRI of the abdomen and pelvis for surveillance of patients with stage 1 testicular cancer post-radical orchiectomy

2020 ◽  
Author(s):  
Rishi Narine ◽  
Heba Osman ◽  
Sirote Wongwaisayawan ◽  
Scott Morgan ◽  
Luke T. Lavallee ◽  
...  
Keyword(s):  
Testicular Cancer ◽  
Radical Orchiectomy ◽  
Stage 1

Testis

2019 ◽  
pp. 279-281
Author(s):  
Peter Hoskin
Keyword(s):  
Lymph Nodes ◽  
Testicular Cancer ◽  
Metastatic Disease ◽  
Combination Chemotherapy ◽  
Palliative Treatment ◽  
Stage I ◽  
Testicular Seminoma ◽  
Resistant Disease

Chapter 12 discusses the role of radiotherapy in testicular cancer and how it is becoming less prominent. The mainstay of treatment is radical orchidectomy and, where there is a risk of metastatic disease, combination chemotherapy. Radiotherapy may be indicated in the following situations: 1) stage I and IIa testicular seminoma delivering prophylactic para-aortic lymph nodes irradiation, and 2) palliative treatment in the management of chemotherapy resistant disease.

Management of Seminomatous Testicular Cancer: A Binational Prospective Population-Based Study From the Swedish Norwegian Testicular Cancer Study Group

2011 ◽  
Vol 29 (6) ◽  
pp. 719-725 ◽  
Author(s):  
Torgrim Tandstad ◽  
Rune Smaaland ◽  
Arne Solberg ◽  
Roy M. Bremnes ◽  
Carl W. Langberg ◽  
...  
Keyword(s):  
Testicular Cancer ◽  
Adjuvant Radiotherapy ◽  
Clinical Stage ◽  
Treatment Protocol ◽  
Late Toxicity ◽  
Population Based ◽  
Testicular Seminoma ◽  
Recommended Treatment ◽  
Cancer Project ◽  
Stage 1

Purpose A binational, population-based treatment protocol was established to prospectively treat and follow patients with seminomatous testicular cancer. The aim was to standardize care for all patients with seminoma to further improve the good results expected for this disease. Patients and Methods From 2000 to 2006, a total of 1,384 Norwegian and Swedish patients were included in the study. Treatment in clinical stage 1 (CS1) was surveillance, adjuvant radiotherapy, or adjuvant carboplatin. In metastatic disease, recommended treatment was radiotherapy in CS2A and cisplatin-based chemotherapy in CS2B or higher. Results At a median follow-up of 5.2 years, 5-year cause-specific survival was 99.6%. In CS1, 14.3% (65 of 512) of patients relapsed following surveillance, 3.9% (seven of 188) after carboplatin, and 0.8% (four of 481) after radiotherapy. We could not identify any factors predicting relapse in CS1 patients who were subjected to surveillance only. In CS2A, 10.9% (three of 29) patients relapsed after radiotherapy compared with no relapses in CS2A/B patients (zero of 73) treated with chemotherapy (P = .011). Conclusion An international, population-based treatment protocol for testicular seminoma is feasible with excellent results. Surveillance remains a good option for CS1 patients. No factors predicted relapse in CS1 patients on surveillance. Despite resulting in a lower rate of relapse than with adjuvant carboplatin, adjuvant radiotherapy has been abandoned in the Swedish and Norwegian Testicular Cancer Project (SWENOTECA) as a recommended treatment option because of concerns of induction of secondary cancers. The higher number of relapses in radiotherapy-treated CS2A patients when compared with chemotherapy-treated CS2A/B patients is of concern. Late toxicity of cisplatin-based chemotherapy versus radiotherapy must be considered in CS2A patients.

scholarly journals An 81-year-old patient with recent diagnosis of classic testicular seminoma

2016 ◽  
Vol 10 (2) ◽  
pp. 143
Author(s):  
Sandro José Martins ◽  
José Carlos De Almeida ◽  
Vitorino Modesto Dos Santos ◽  
Ana Carolina Vieira Cançado ◽  
Giovanna Ferraz Cavalcanti ◽  
...  
Keyword(s):  
Early Stage ◽  
Testicular Tumor ◽  
Population Based ◽  
Medical Attention ◽  
Left Testis ◽  
Testicular Seminoma ◽  
Left Testicle ◽  
First Choice ◽  
Recent Diagnosis ◽  
Radical Orchiectomy

An old patient with recent diagnosis of classic seminoma is reported. The tumor of left testicle was heralded by tenderness about 30 days before medical attention and enlarged testis confirmation. There was antecedent of left testis hypotrophy treated with testosterone and a surgery for varicocele at 15 years of age. Clinical hypothesis of testicular tumor was strengthened by ultrasonography images and elevated tumor markers (lactate dehydrogenase, <span>α</span>-fetoprotein, and <span>β</span>-hCG). Radical orchiectomy was performed and a classic seminoma (pT1pNx) was diagnosed. Active waiting was the first choice for management, but six months later a retroperitoneal mass with lymph node enlargement were found, and he underwent four sessions of carboplatin (AUC 5), bleomycin and etoposide (BEP regimen). Asymptomatic, he was referred to outpatient surveillance on Oncology. Population-based studies about frequency and outcome of early-stage testis seminoma in elderly are scarce. Case studies might contribute to the knowledge about this condition.

Surveillance of Stage 1 Non-Seminomatous Testicular Cancer — A Preliminary Report of the EORTC GU-Cooperative Group Surveillance Study

1994 ◽  
pp. 195-199
Author(s):  
A.T. van Oosterom ◽  
C. Vendrik ◽  
J. Keizer ◽  
J.P. Droz ◽  
J. Schornagel ◽  
...  
Keyword(s):  
Testicular Cancer ◽  
Preliminary Report ◽  
Surveillance Study ◽  
Cooperative Group ◽  
Stage 1

scholarly journals Testicular Abscess an Unusual Cause for Febrile Neutropenia

2008 ◽  
Vol 8 ◽  
pp. 953-955
Author(s):  
Tal Grenader
Keyword(s):  
Febrile Neutropenia ◽  
Testicular Cancer ◽  
Metastatic Disease ◽  
Surgical Complications ◽  
Related Factors ◽  
Platinum Based Chemotherapy ◽  
Testicular Abscess ◽  
Chemotherapy Dose ◽  
Good Risk

Patients with good-risk disseminated testicular cancer are effectively managed with platinum-based chemotherapy. Febrile neutropenia is a dose-limiting event for many chemotherapy regimens. The risk of developing febrile neutropenia is related both to the chemotherapy dose and schedule, and to patient-related factors. Among patients who require ongoing chemotherapy for metastatic disease, it is very unusual for surgical complications to delay the initiation of chemotherapy. We describe a patient who developed febrile neutropenia with testicular abscess when treated with BEP 2 weeks following inguinal orchiectomy.

A case of an infertile man with nonobstructive azoospermia after radical orchiectomy for testicular cancer

2015 ◽  
Vol 112 ◽  
pp. 135
Author(s):  
Yutaka Fujisue ◽  
Junko Kono ◽  
Yatsugu Kotake ◽  
Hiroshi Masuda ◽  
Yoshiki Yamashita ◽  
...  
Keyword(s):  
Testicular Cancer ◽  
Nonobstructive Azoospermia ◽  
Radical Orchiectomy

HISTOLOGIC PATTERNS OF SPERMATOGENESIS IN TESTICULAR CANCER: FEASIBILITY OF BENCHSIDE SPERM RETRIEVAL AT TIME OF RADICAL ORCHIECTOMY

2009 ◽  
Vol 181 (4S) ◽  
pp. 199-199
Author(s):  
Abdulaziz Baazeem ◽  
Jason M Boman ◽  
Philippe Violette ◽  
Armand Zini
Keyword(s):  
Testicular Cancer ◽  
Sperm Retrieval ◽  
Radical Orchiectomy
Sign in / Sign up

Export Citation Format

Share Document